CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

Table 1 Patient characteristics

Patient ID	Sex	Age	Stage	Location of Metastasis	Treme-limumab (mg/kg q3mo)	MART-1/DC	Toxicities During the First Cycle	Tumor Response
NRA11	M	57	M1c	LN, Muscle	10	Y	-	PD
NRA12	M	55	M1c	Lung, Liver	10	Y	-	PD
NRA13	F	34	M1c	SC, LN, Muscle, Breast	10	Y	-	PD
NRA14	M	57	IIIc	SC	15	Y	-	CR
NRA15	M	48	M1a	LN	15	Y	-	PR
NRA16	F	61	M1a	S.C.	15	Y	-	PD
GA 5	M	65	M1c	Skin, LN, Adrenal	15	N	-	PR, then PD
GA 7	M	62	IIIc	Skin	15	N	G2 Pruritus	PD
GA 8	F	48	M1c	SC	15	N	G2 Diarrhea	PD
GA 9	M	52	M1c	LN, Bone	15	N	-	PD
GA 11	M	47	M1c	LN	15	N	-	PD
GA 12	M	76	M1c	Skin	15	N	G3 Colitis	PD
GA 13	M	37	M1a	LN	15	N	G2 Hypophysitis	PD
GA 14	M	38	M1c	SC, Muscle	15	N	-	PD
GA 15	M	58	M1c	Brain, Bowel, Liver	15	N	-	PD
GA 18	F	49	M1a	Skin	15	N	-	CR
GA 19	M	55	M1c	LN, Brain	15	N	G2 Diarrhea	PD
GA 21	M	71	M1c	Skin, SC, LN, Liver, Spleen	15	N	-	PD
GA 23	M	27	M1b	Lung	15	N	-	PD
GA 24	M	81	M1c	SC, Lung	15	N	-	PD
GA 25	M	71	M1c	LN	15	N	-	PD
GA 26	M	68	M1b	LN, Lung	15	N	G3 Diarrhea	PD
GA 27	M	52	M1c	SC	15	N	G2 Pruritus	PD
GA 28	M	48	M1c	LN, Lung	15	N	-	PD
GA 29	F	79	IIIc	Skin, SC	15	N	G2 Diarrhea	CR
GA 32	M	36	M1c	Muscle	15	N	-	PD
GA 33	F	49	IIIc	Skin	15	N	-	CR

MART-1/DC: MART-1_26–35 peptide pulsed dendritic cells; G: grade; LN: lymph node; SC: subcutaneous; M: male; F: female; Y: yes; N: no; PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response.

ISSN: 1479-5876